Challenges in Vaccine Production and Rapid Scale up to Meet Emerging Pandemic Threats
Over 95 percent of US flu vaccine is manufactured in eggs. This provides ~50 million vaccine doses annually but requires 8-10 months. In a pandemic, more doses must be produced quickly and therefore rapid, scalable methods must be used. Cell-based production and
disposable bioreactors can accelerate production by several months and enable manufacture of larger quantities. This presentation reviews alternative production methods for influenza vaccines.